Fulgent Genetics Inc (FLGT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 12-2021 | 09-2021 | 06-2021 | 03-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 506,239 | 402,562 | 280,338 | 200,691 | 214,310 |
| Depreciation Amortization | 18,600 | 13,003 | 7,511 | 3,225 | 3,819 |
| Income taxes - deferred | -8,188 | -6,574 | -3,055 | -786 | -1,775 |
| Accounts receivable | 42,300 | 65,003 | 32,460 | -34,595 | -178,480 |
| Accounts payable and accrued liabilities | -12,206 | -9,002 | -10,256 | -6,256 | 22,617 |
| Other Working Capital | -2,676 | 39,074 | 17,107 | 25,285 | -91,451 |
| Other Operating Activity | -5,492 | -42,575 | -14,815 | 45,615 | 171,588 |
| Operating Cash Flow | $538,577 | $461,491 | $309,290 | $233,179 | $140,628 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -710,490 | -462,423 | -390,269 | -205,012 | -304,440 |
| PPE Investments | -23,749 | -17,807 | -14,414 | -11,479 | -35,122 |
| Net Acquisitions | -61,868 | -61,868 | -18,509 | N/A | N/A |
| Purchase Of Investment | N/A | N/A | N/A | N/A | -3,971 |
| Sale Of Investment | 269,591 | 155,809 | 51,696 | N/A | 17,095 |
| Purchase Sale Intangibles | -32 | N/A | N/A | N/A | N/A |
| Other Investing Activity | -20,032 | -20,000 | 0 | 0 | 0 |
| Investing Cash Flow | $-546,548 | $-406,289 | $-371,496 | $-216,491 | $-326,438 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | N/A | N/A | 58 | 29 | 15,019 |
| Debt Repayment | -11 | -3 | N/A | N/A | N/A |
| Common Stock Issued | 89,561 | 75,711 | 75,724 | 47,831 | 246,294 |
| Common Stock Repurchased | -4,155 | -3,467 | -552 | -513 | -62 |
| Other Financing Activity | 10 | 10 | 10 | 0 | 0 |
| Financing Cash Flow | $85,405 | $72,251 | $75,240 | $47,347 | $261,251 |
| Exchange Rate Effect | 34 | -2 | 1 | N/A | 20 |
| Beginning Cash Position | 87,426 | 87,426 | 87,426 | 87,426 | 11,965 |
| End Cash Position | 164,894 | 214,877 | 100,461 | 151,461 | 87,426 |
| Net Cash Flow | $77,468 | $127,451 | $13,035 | $64,035 | $75,461 |
| Free Cash Flow | |||||
| Operating Cash Flow | 538,577 | 461,491 | 309,290 | 233,179 | 140,628 |
| Capital Expenditure | -23,812 | -17,829 | -14,427 | -11,492 | -35,130 |
| Free Cash Flow | 514,765 | 443,662 | 294,863 | 221,687 | 105,498 |